Quarterly Result21 May 2026, 08:51 pm
Aurobindo Pharma FY26: Revenue Up 6.1% YoY to ₹33,653 Cr
AI Summary
Aurobindo Pharma Ltd announced its consolidated financial results for Q4 and year ended March 31, 2026. Revenue from operations increased by 5.6% YoY to ₹8,853 Cr, with European business crossing €1bn+ in revenues in FY26. Net profit for the quarter stood at ₹921 Cr. The company received final approval for 9 ANDAs from the USFDA. Strong net cash position as on 31-Mar-26 after payment for acquisition of Khandelwal laboratories (non-oncology) business at USD 317mn.
Key Highlights
- Revenue from Operations increased by 5.6% YoY to ₹8,853 Cr.
- European business achieved €1bn+ in revenues in FY26, Q4 revenues up 30.2% YoY to ₹2,795 Cr.
- Net Profit for the quarter stood at ₹921 Cr.
- Received final approval for 9 ANDAs from the USFDA.
- FY26 Revenue from operations increased by 6.1% to ₹33,653 Cr.